Cronos Group Inc. (CRON.TO)
CAD 2.53
(2.02%)
CAD 2.53
(2.02%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 43.96 Million USD | -38.98% |
| 2022 | 72.04 Million USD | 13.52% |
| 2021 | 63.46 Million USD | -70.82% |
| 2020 | 217.51 Million USD | -36.29% |
| 2019 | 341.41 Million CAD | 839.82% |
| 2018 | 36.32 Million CAD | 211.59% |
| 2017 | 11.65 Million CAD | 69.91% |
| 2016 | 6.86 Million CAD | 215.09% |
| 2015 | 2.17 Million CAD | 258.74% |
| 2014 | 607.04 Thousand CAD | 58.86% |
| 2013 | 382.12 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 35.75 Million USD | -18.66% |
| 2024 Q2 | 35.25 Million USD | -1.4% |
| 2023 Q3 | 33.34 Million USD | 5.28% |
| 2023 FY | 43.96 Million USD | -38.98% |
| 2023 Q1 | 33.17 Million USD | -53.95% |
| 2023 Q2 | 31.67 Million USD | -4.52% |
| 2023 Q4 | 43.96 Million USD | 31.83% |
| 2022 Q3 | 46.22 Million USD | -2.17% |
| 2022 FY | 72.04 Million USD | 13.52% |
| 2022 Q1 | 49.63 Million USD | -21.8% |
| 2022 Q4 | 72.04 Million USD | 55.85% |
| 2022 Q2 | 47.25 Million USD | -4.8% |
| 2021 Q2 | 208.69 Million USD | -33.32% |
| 2021 FY | 63.46 Million USD | -70.82% |
| 2021 Q1 | 313 Million USD | 43.9% |
| 2021 Q4 | 63.46 Million USD | -19.44% |
| 2021 Q3 | 78.77 Million USD | -62.25% |
| 2020 Q2 | 247.24 Million USD | 16.26% |
| 2020 Q3 | 154.44 Million USD | -37.53% |
| 2020 Q4 | 217.51 Million USD | 40.84% |
| 2020 FY | 217.51 Million USD | -36.29% |
| 2020 Q1 | 212.65 Million USD | -37.71% |
| 2019 FY | 341.41 Million CAD | 839.82% |
| 2019 Q4 | 341.41 Million CAD | -26.46% |
| 2019 Q3 | 464.26 Million CAD | -57.76% |
| 2019 Q2 | 1.09 Billion CAD | -15.07% |
| 2019 Q1 | 1.29 Billion CAD | 3462.75% |
| 2018 Q4 | 36.32 Million CAD | 285.19% |
| 2018 Q1 | 6.92 Million CAD | -40.56% |
| 2018 FY | 36.32 Million CAD | 211.59% |
| 2018 Q3 | 9.43 Million CAD | 51.89% |
| 2018 Q2 | 6.2 Million CAD | -10.4% |
| 2017 Q3 | 9.58 Million CAD | 203.37% |
| 2017 Q2 | 3.16 Million CAD | -47.3% |
| 2017 FY | 11.65 Million CAD | 69.91% |
| 2017 Q1 | 5.99 Million CAD | -12.6% |
| 2017 Q4 | 11.65 Million CAD | 21.59% |
| 2016 Q2 | 318.69 Thousand CAD | -84.46% |
| 2016 Q4 | 6.86 Million CAD | -0.22% |
| 2016 Q3 | 6.87 Million CAD | 2057.84% |
| 2016 FY | 6.86 Million CAD | 215.09% |
| 2016 Q1 | 2.05 Million CAD | -5.84% |
| 2015 Q3 | 1.68 Million CAD | 5.86% |
| 2015 Q1 | 714.5 Thousand CAD | 0.0% |
| 2015 FY | 2.17 Million CAD | 258.74% |
| 2015 Q4 | 2.17 Million CAD | 28.87% |
| 2015 Q2 | 1.59 Million CAD | 123.41% |
| 2014 Q3 | 39.3 Thousand CAD | 7.81% |
| 2014 FY | 607.04 Thousand CAD | 58.86% |
| 2014 Q2 | 36.45 Thousand CAD | 0.0% |
| 2013 FY | 382.12 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aurora Cannabis Inc. | 236.8 Million CAD | 81.436% |
| Avicanna Inc. | 13.99 Million CAD | -214.03% |
| Avant Brands Inc. | 33.22 Million CAD | -32.317% |
| Cardiol Therapeutics Inc. | 8.45 Million CAD | -420.002% |
| Crescita Therapeutics Inc. | 5.77 Million CAD | -661.098% |
| Knight Therapeutics Inc. | 198.62 Million CAD | 77.867% |
| MediPharm Labs Corp. | 10.93 Million CAD | -302.131% |
| OrganiGram Holdings Inc. | 26.83 Million CAD | -63.838% |
| Canopy Growth Corporation | 799.82 Million CAD | 94.504% |
| Willow Biosciences Inc. | 3.23 Million CAD | -1258.078% |
| Auxly Cannabis Group Inc. | 210.85 Million CAD | 79.151% |